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Abstract
Background: Two antigenically distinct influenza B lineages have co-circulated since the 1980s, yet inactivated
trivalent influenza vaccines (TIVs) include strains of influenza A/H1N1, A/H3N2, and only one influenza B from either
the Victoria or Yamagata lineage. This means that exposure to B-lineage viruses mismatched to the TIV is frequent,
reducing vaccine protection. Formulations including both influenza B lineages could improve protection against
circulating influenza B viruses. We assessed a candidate inactivated quadrivalent influenza vaccine (QIV) containing
both B lineages versus TIV in adults in stable health.
Methods: A total of 4659 adults were randomized 5:5:5:5:3 to receive one dose of QIV (one of three lots) or a TIV
containing either a B/Victoria or B/Yamagata strain. Hemagglutination-inhibition assays were performed
pre-vaccination and 21-days after vaccination. Lot-to-lot consistency of QIV was assessed based on geometric mean
titers (GMT). For QIV versus TIV, non-inferiority against the three shared strains was demonstrated if the 95%
confidence interval (CI) upper limit for the GMT ratio was ≤1.5 and for the seroconversion difference was ≤10.0%;
superiority of QIV versus TIV for the alternate B lineage was demonstrated if the 95% CI lower limit for the GMT
ratio was > 1.0 and for the seroconversion difference was > 0%. Reactogenicity and safety profile of each vaccine
were assessed. Clinicaltrials.gov: NCT01204671.
Results: Consistent immunogenicity was demonstrated for the three QIV lots. QIV was non-inferior to TIV for the
shared vaccine strains, and was superior for the added alternate-lineage B strains. QIV elicited robust immune
responses against all four vaccine strains; the seroconversion rates were 77.5% (A/H1N1), 71.5% (A/H3N2), 58.1%
(B/Victoria), and 61.7% (B/Yamagata). The reactogenicity and safety profile of QIV was consistent with TIV.
Conclusions: QIV provided superior immunogenicity for the additional B strain compared with TIV, without
interfering with antibody responses to the three shared antigens. The additional antigen did not appear to alter the
safety profile of QIV compared with TIV. This suggests that the candidate QIV is a viable alternative to TIV for use in
adults, and could potentially improve protection against influenza B.
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Background
Despite widespread vaccination programs, influenza re-
mains a major cause of hospitalization and death in
adults, particularly among older adults and those with
chronic illnesses [1]. Among healthy adults, influenza is
an important cause of outpatient medical visits and
worker absenteeism, burdening health care systems and
leading to substantial societal costs [2-4].
Inactivated trivalent influenza vaccines (TIVs), used for
vaccination against seasonal influenza, include two influ-
enza A strains (A/H1N1, A/H3N2) and one influenza B
strain, selected using surveillance-based forecasts [5]. Two
antigenically distinct influenza B lineages (B/Yamagata and
B/Victoria) emerged globally in humans in the early 1980s,
and have co-circulated in the US since 2000. Furthermore,
vaccination against one lineage provides limited or no
cross-protection against B strains from the alternate lineage
[6-8]. This means that vaccine effectiveness is likely to be
compromised during seasons when lineage-mismatched
influenza B strains are prevalent. In a recent meta-analysis
of randomized controlled trials reporting laboratory-
confirmed influenza in children, adults, and elderly adults,
in seven trials where the TIV was mismatched for influenza
B strains, the vaccine efficacy was 52% (95% CI: 19, 72),
whereas in five trials where the TIV was matched for influ-
enza B, the vaccine efficacy was 77% (95% CI: 18, 94) [9].
During about half of the influenza seasons in the past
decade, the recommended TIV was mismatched for the
circulating influenza B lineage; between 2000 and 2011,
the predominant influenza B viruses detected by US sur-
veillance in 6 out of 11 influenza seasons were B lineage
mismatched for the recommended TIV, and mismatch
was observed in Europe during 4 out of 8 influenza sea-
sons between 2003 and 2011 [5,10]. The use of quadriva-
lent vaccines including an influenza B strain of each
lineage is likely to improve vaccine protection. In a mod-
eling study conducted by the US Center for Disease
Control and Prevention (CDC), based on the clinical
burden of influenza illness and viral surveillance, the use
of a quadrivalent vaccine rather than a TIV between
1999 and 2009 could have resulted in between 2200 and
970,000 fewer influenza illnesses, between 14 and 8200
fewer influenza-associated respiratory hospitalizations,
and between 1 and 485 fewer influenza-related respira-
tory deaths in the US [11].
In February 2012, the World Health Organization
(WHO) recommended strains for inclusion in quadrivalent
vaccines for use in the 2012/2013 influenza season in the
Northern Hemisphere, heralding a new era in influenza
vaccination strategy [12]. In the same month, FluMist®
(MedImmune), a live attenuated influenza vaccine for in-
tranasal administration in people aged 2–49 years, became
the first quadrivalent influenza vaccine formulation to gain
approval in the US [13,14]. In this paper, we discuss a vac-
cine trial conducted in adults and elderly adults in stable
health, which evaluated an established TIV for intramuscu-
lar administration (Fluarix™; GlaxoSmithKline Vaccines),
formulated with an additional influenza B strain.
The Phase III, multinational study was randomized
and partially-blind and assessed the immunogenicity,
reactogenicity, and safety of the candidate inactivated
quadrivalent split virion influenza vaccine (QIV) versus
two TIVs containing a strain from each of the B lineages.
The main aims were to demonstrate the immunological
consistency of three QIV lots, to show the non-inferiority
of hemagglutination inhibition (HI) antibody responses
for QIV versus TIVs against shared influenza A and B
strains, and to assess the superiority of HI antibody re-
sponses of QIV versus TIVs for the alternate B lineage.
Methods
This Phase III, randomized, partially-blind, multinational
study evaluated the immunogenicity, reactogenicity and
safety of a candidate QIV versus TIV in adults aged
≥18 years. The study was conducted between October
2010 and June 2011 in Germany, Romania, Spain, Korea,
Taiwan and the US.
Eligible subjects were aged ≥18 years and were in
stable health without significant pulmonary, cardiovas-
cular, hepatic or renal disease. Subjects were excluded if
they had received any seasonal influenza vaccination
within 6 months or any investigational product within
30 days before vaccination in this study. Other criteria
for exclusion were history of Guillain Barré syndrome,
hypersensitivity to a previous dose of influenza vaccine
or its components, immunosupression, or receipt of im-
munoglobulins or blood products within 3 months be-
fore vaccination.
The study was conducted in accordance with the Good
Clinical Practice guidelines, the Declaration of Helsinki and
applicable local regulations. All study documents were ap-
proved by independent national or regional ethics commit-
tees or institutional review boards. All subjects provided
written informed consent. Clintrials.gov NCT01204671.
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Vaccines and randomization
The study vaccines were developed and manufactured by
GlaxoSmithKline (GSK), Dresden, Germany. The QIV
candidate was a thimerosal-free, inactivated split virion
vaccine containing two influenza A strains (A/California/
7/2009 [H1N1] and A/Victoria/210/2009 [H3N2], an
A/Perth/16/2009-like strain) and one influenza B strain
(B/Brisbane/60/2008 [Victoria-lineage]) recommended
for the influenza season 2010–2011 in the Northern
Hemisphere, and one influenza B strain from the B/
Yamagata lineage (B/Brisbane/3/2007, a B/Florida/4/
2006 like strain previously recommended for the 2008–2009
influenza season). The TIVs contained B/Victoria (TIV-
Vic) or TIV-B/Yamagata (TIV-Yam). TIV-Vic (Fluarix™, a
trademark of the GlaxoSmithKline Vaccines) was a
thimerosal-free, inactivated, split virion TIV containing
the strains recommended for the influenza season 2010–
2011 in the Northern Hemisphere. TIV-Yam differed
from TIV-Vic only in the influenza B virus lineage
(B/Brisbane/3/2007 [Yamagata-lineage]). The vaccines
contained 15 μg of each hemagglutinin antigen, and
were given as a 0.5 ml dose.
A randomization list was generated by the study spon-
sor using MATEX, a program developed for SAS® (Cary,
NC, USA). Treatment allocation at each center was
performed via an internet-based system; groups had
an equal distribution of subjects aged 18–64 years
versus ≥ 65 years and a minimization algorithm was used
to account for center, and influenza vaccination in the pre-
vious season. Subjects were randomized 5:5:5:5:3 to receive
QIV lot 1, 2, or 3, TIV-Vic, or TIV-Yam. All personnel and
subjects were blind to the vaccine allocation of QIV or
TIV-Vic, whereas TIV-Yam was open-label. Subjects in the
QIV and TIV-Vic groups were followed-up for 6 months,
whereas the study stopped at Day 21 for the TIV-Yam
group so these subjects could choose to receive a licensed
vaccine for the current season. Subjects received one dose
of vaccine in the deltoid of the non-dominant arm.
Assessments
Immunogenicity
Blood was collected in a subset of subjects for sero-
logical testing before vaccination (Day 0) and at Day 21
post-vaccination. Hemagglutination inhibition (HI) anti-
body titers against the vaccine strains were assessed at
GlaxoSmithKline Vaccines central laboratory using vali-
dated assay methods as previously described [15].
Immunogenicity parameters were geometric mean
titer (GMT), seroprotection rate (SPR; proportion with
post-vaccination titer ≥ 1:40), seroconversion rate (SCR;
proportion with antibody titer < 1:10 at baseline and
with post-vaccination titer of ≥1:40, or pre-vaccination
titer of ≥ 1:10 and a ≥ 4-fold post-vaccination increase in
titer), and seroconversion factor (SCF; geometric mean
of the ratio between pre-vaccination and post-vaccination
reciprocal HI titers). Subjects with HI antibody titers
of ≥ 1:10 were considered to be seropositive.
Reactogenicity and safety
Subjects used diary cards to record solicited injection
site adverse events (pain, redness and swelling) and gen-
eral adverse events (fatigue, fever, gastrointestinal symp-
toms, headache, joint pain, general muscle ache and
shivering) during the 7-day post-vaccination period. In-
tensity of solicited symptoms was graded on a standard
scale (0–3); Grade 1 symptoms were defined as those
not interfering with normal activities and Grade 3 symp-
toms were defined as those preventing normal activities
(Grade 3 redness and swelling: diameter > 100 mm;
Grade 3 fever: temperature > 39°C [> 102.2°F]).
Unsolicited adverse events (AEs), serious adverse
events (SAEs), and medically-attended adverse events
(MAEs) were collected and were coded using the
Medical Dictionary for Regulatory Activities. All solicited
injection site symptoms were considered vaccination-
related, and investigators judged causality with the vaccin-
ation for all other events.
Objectives
The co-primary objectives were to evaluate for the study
population overall: the lot-to-lot consistency of three
QIV lots based on GMTs at Day 21 post-vaccination; the
non-inferiority of GMTs and SCRs at Day 21 for QIV
versus TIV-Vic and TIV-Yam against the shared strains,
and the superiority of GMTs and SCRs at Day 21 for
QIV versus TIV-Vic and TIV-Yam against the alternate-
lineage B strains (i.e. QIV versus TIV-Vic against B/
Yamagata, and QIV versus TIV-Yam against B/Victoria).
The secondary objectives were to describe: immuno-
genicity parameters in the population overall and strati-
fied by age (18–64 years and ≥ 65 years); solicited adverse
events (AEs) during the 7 day post-vaccinated period; un-
solicited AEs during the 21-day post-vaccination period;
SAEs and MAEs during the 6 months study period in the
QIV and TIV-Vic group, and for 21 days post-vaccination
in the open-label TIV-Yam group.
Statistical analyses
The target sample size for the immunogenicity sub-
cohort was 570 evaluable subjects, based on the global
power to meet all co-primary objectives of at least 90%.
A target sample of 1000 subjects per lot in the QIV
group was based on the power to evaluate lot-to-lot
consistency estimated using PASS, equivalence test of
two means using differences (α = 5.0%) and applying the
Zmin test principle. The sample size of 1000 subjects
in the TIV-Vic group was based on the power for evalu-
ating the non-inferiority and superiority objectives
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estimated using PASS, one-sided two-sample t-test for a
difference of means (α = 2.5%; for HI antibody GMT
ratios) and on the difference of proportions (α = 2.5%;
for HI antibody SCRs). The total sample size of 4600
was determined to allow 3000 subjects in the QIV group,
which would enable the detection of AEs occurring at a
rate of 0.1%.
Adjusted GMTs were estimated using an ANCOVA
model fitted on log10 transformed post-vaccination HI
titer including treatment as fixed effect and baseline titer
as a covariate. The SCR difference and the two-sided
95% CI of the SCR differences were computed after fit-
ting a logistic regression on the SCR, including vaccine
group as a fixed effect and baseline titer as a covariate.
The co-primary confirmatory analyses were performed
in the following order: Lot-to-lot consistency was based
on adjusted GMT ratios for pairwise comparisons of
QIV lots (lot 1/lot 2, lot 1/lot 3, lot 2/lot 3) for each
strain; the pair with the largest GMT ratio for each
strain was evaluated, and lot-to-lot consistency was
demonstrated if the two-sided 95% CI limit was between
0.67 and 1.5 for all four strains. Non-inferior immuno-
genicity of QIV versus TIV for shared strains was dem-
onstrated if the upper limit of the two-sided 95% CI for
the adjusted GMT ratio of TIV/QIV did not exceed 1.5,
and the upper limit of the two-sided 95% CI for the SCR
Enrolled N=4659
Total vaccinated cohort N=4656
Completed study n=4597
Per-protocol immunogenicity sub-cohort n=2951 [Unknown completion status n=2]
Withdrawals:
Consent withdrawal n=17
Lost to follow-up n=22 
SAE n=13
Non-serious AE n=1
Exclusion criteria not met after 
enrolment n=1
Not reachable via telephone n=2 






Study vaccine not administered 
according to protocol n=1
Protocol violation 
(inclusion/exclusion criteria) n=7
Non-compliance with blood 
sampling schedule n=25
Essential serological data missing 
n=20
[Unknown completion status n=2]
Eliminations:





Non-compliance with blood sampling 
schedule n=7








Non-compliance with blood 
sampling schedule n=6
Essential serological data missing 
n=5

























Figure 1 Subject flow. Footnote: QIV, inactivated quadrivalent influenza vaccine; TIV-Vic, inactivated trivalent influenza vaccine Victoria lineage B
strain; TIV-Yam, inactivated trivalent influenza vaccine Yamagata lineage B strain; SAE, serious adverse event.
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difference (TIV minus QIV) did not exceed 10.0. Super-
ior immunogenicity of QIV versus TIV for the alternate-
lineage B strain was demonstrated if the lower limit of
the two-sided 95% CI on the adjusted GMT ratio (QIV/
TIV-Vic and QIV/TIV-Yam) was greater than 1.0, and
the lower limit of the two-sided 95% CI for the SCR
difference (QIV minus TIV-Vic or TIV-Yam) was greater
than 0.
Immunogenicity parameters were described with 95%
CIs. Immunogenicity analyses were performed on the
per-protocol immunogenicity sub-cohort including sub-
jects who met the eligibility criteria and complied with
Table 1 Demographic and clinical characteristics in the total vaccinated cohort
QIV TIV-Vic TIV-Yam
N = 3036 N = 1010 N = 610
Mean age, years (SD; median; range) 57.9 (17.7; 64.0; 18.0–92.0) 58.1 (17.8; 64.0; 18.0–92.0) 58.1 (17.9; 65.0; 18.0–90.0)
Sub-groups: mean age, years (SD, median) 43.5 (13.58; 44.0) 43.7 (13.84; 44.0) 43.5 (14.01; 46.0)
18–64 years 72.3 (5.45; 71.0) 72.5 (5.53; 71.0) 72.4 (5.39; 72.0)
≥65 years
Male, n (%) 1291 (42.5) 462 (45.7) 267 (43.8)
Hispanic/Latino ethnicity, n (%) 134 (4.4) 47 (4.7) 25 (4.1)
Not Hispanic/Latino ethnicity, n (%) 2902 (95.6) 963 (95.3) 585 (95.9)
Geographic ancestry 2078 (68.4) 699 (69.2) 414 (67.9)
European heritage / Caucasian 22 (0.7) 7 (0.7) 4 (0.7)
Arabic/north American heritage / Caucasian 805 (26.5) 270 (26.7) 162 (26.5)
Asian 106 (3.5) 26 (2.6) 21 (3.4)
African heritage / African American 6 (0.2) 2 (0.2) 3 (0.5)
American Indian or native Alaskan 2 (0.1) 0 0
Native Hawaiian or other pacific islander 17 (0.6) 6 (0.6) 6 (1.0)
Other
Medical history, n (%) 533 (17.56) 153 (15.15) 106 (17.38)
Cardiovascular disease† 457 (15.05) 129 (12.77) 89 (14.59)
Diabetes 293 (9.65) 104 (10.30) 57 (9.34)
Chronic respiratory disease 117 (3.85) 39 (3.86) 26 (4.26)
Cancer 76 (2.50) 17 (1.68) 13 (2.13)
Cerebrovascular disease 60 (1.98) 23 (2.28) 13 (2.13)
Chronic hepatic disease 43 (1.42) 11 (1.09) 6 (0.98)
Chronic renal disease
Received seasonal influenza vaccination in
at least one of previous three seasons, n (%)
2395 (78.9) 788 (78.0) 483 (79.2)
Received A/H1N1pdm09 vaccination during the previous season 848 (27.9) 289 (28.6) 165 (27.0)
QIV inactivated quadrivalent influenza vaccine, SD standard deviation, TIV-Vic inactivated trivalent influenza vaccine Victoria lineage B strain, TIV-Yam inactivated
trivalent influenza vaccine Yamagata lineage B strain, †Excluding hypertension.
Table 2 Lot-to-lot consistency of QIV lots based on HI-assay based GMTs at Day 21 in the per-protocol immunogenicity
sub-cohort
Min† Max‡ Adjusted GMT ratio
n Adjusted GMT n Adjusted GMT Min/Max¶§ (95% CI)
A/California/7/2009 (H1N1) 600 196.5 599 209.0 0.94 (0.80–1.10)
A/Victoria/210/2009 (H3N2) 600 306.8 599 330.6 0.93 (0.81–1.06)
B/Brisbane/60/2008 (Victoria lineage) 600 410.7 599 396.7 1.04 (0.93–1.15)
B/Brisbane/3/2007 (Yamagata lineage) 600 605.0 599 599.0 1.01 (0.90–1.13)
†Lot with lowest GMT; ‡Lot with highest GMT; ¶Pair with the largest GMT ratio for each strain from pairwise comparisons was assessed and consistency was
demonstrated if the 2-sided 95% CI limit was between 0.67 and 1.5 for all four strains; §for each strain, lot 1/lot 2.
CI confidence interval, GMT geometric mean titer, HI hemagglutination inhibition, QIV quadrivalent inactivated influenza vaccine.
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the protocol (per-protocol immunogenicity cohort), and
whom were allocated to the immunogenicity sub-cohort
(the first 600 subjects randomized in each group account
the age stratification and the minimization factors), and
for whom data were available at the evaluation time
point.
Solicited and unsolicited AEs were tabulated with 95%
CIs. Reactogenicity and safety analyses were performed
on the total vaccinated cohort.
Results
A total of 4659 subjects were enrolled, of which 4656 sub-
jects were vaccinated: Germany n = 651, Romania n = 650,
Spain n = 672, Korea n = 832, Taiwan n = 400 and the US
n = 1451. A total of 4597 subjects completed the study
(Figure 1). The reasons for withdrawals and exclusion are
shown in Figure 1. The demographic characteristics were
balanced across all study groups (Table 1). A review of the
reported medical history revealed that cardiovascular
Table 3 Non-inferiority of QIV versus TIVs against shared strains according to HI-assay based GMT and SCR at Day 21
in the per-protocol immunogenicity sub-cohort
Vaccine antigen Adjusted GMT Adjusted GMT ratio (95% CI)†
TIV-Vic + TIV-Yam, N = 1135 QIV, N = 1801 TIV-Vic + TIV-Yam/QIV
A/California/7/2009 (H1N1) 214.8 201.6 1.07 (0.96, 1.18)
A/Victoria/210/2009 (H3N2) 312.2 318.5 0.98 (0.90, 1.07)
B/Brisbane/60/2008 TIV-Vic, N = 605 QIV, N = 1801 TIV-Vic/QIV
(Victoria lineage) 395.3 404.2 0.98 (0.9, 1.07)
B/Brisbane/3/2007 TIV-Yam, N = 530 QIV, N = 1801 TIV-Yam/QIV
(Yamagata lineage) 584.7 600.8 0.97 (0.89, 1.07)
Number seroconverted (SCR) SCR difference (95% CI)‡
TIV-Vic + TIV-Yam, N = 1135 QIV, N = 1801 TIV-Vic + TIV-Yam minus QIV
A/California/7/2009 (H1N1) 892 (78.6%) 1396 (77.5%) 1.08 (−2.03, 4.11)
A/Victoria/210/2009 (H3N2) 769 (67.8%) 1287 (71.5%) −3.71 (−7.15, −0.30)
B/Brisbane/60/2008 TIV-Vic, N = 605 QIV, N = 1801 TIV-Vic minus QIV
(Victoria lineage) 335 (55.4%) 1046 (58.1%) −2.71 (−7.29, 1.83)
B/Brisbane/3/2007 TIV-Yam, N = 530 QIV, N = 1801 TIV-Yam minus QIV
(Yamagata lineage) 313 (59.1%) 1112 (61.7%) −2.69 (−7.47, 2.01)
†Non-inferiority was demonstrated if the lower limit of the 95% CI was ≤1.5; ‡Non-inferiority was demonstrated if the lower limit of the 95% CI ≤10.0.
CI confidence interval, GMT geometric mean titer, HI Hemagglutination inhibition, SCR seroconversion rate (proportion with pre-vaccination titer <1:10 and a
post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer), TIV trivalent inactivated influenza vaccine,
Vic Victoria lineage B strain, Yam Yamagata lineage B strain, QIV quadrivalent inactivated influenza vaccine.
Table 4 Superiority of QIV versus TIVs against alternate lineage B strains according to HI-assay based GMT and SCR at
Day 21 in the per-protocol cohort for immunogenicity
Vaccine antigen TIV-Vic TIV-Yam QIV Superiority analysis
N = 605 N = 530 N = 1081
Adjusted GMT Adjusted GMT ratio (95% CI)†
B/Brisbane/3/2007 (Yamagata lineage) 387.7 – 601.2 QIV/TIV-Vic
1.55 (1.41, 1.70)
B/Brisbane/60/2008 (Victoria lineage) – 259.4 403.5 QIV/TIV-Yam
1.56 (1.42, 1.70)
Number seroconverted (SCR) SCR difference (95% CI)‡
B/Brisbane/3/2007 (Yamagata lineage) 276 (45.6%) – 1112 (61.7%) QIV minus TIV-Vic
16.12% (11.54, 20.65)
B/Brisbane/60/2008 (Victoria lineage) – 252 (47.5%) 1046 (58.1%) QIV minus TIV-Yam
10.53% (5.70, 15.33)
†Superiority was demonstrated if the lower limit of the 95% CI was > 1.0; ‡Superiority was demonstrated if the lower limit of the 95% CI was > 0%.
CI confidence interval, GMT geometric mean titer, HI Hemagglutination inhibition, SCR seroconversion rate (proportion with pre-vaccination titer < 1:10 and a
post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer), TIV-Vic inactivated trivalent influenza
vaccine Victoria lineage B strain, TIV-Yam inactivated trivalent influenza vaccine Yamagata lineage B strain, QIV inactivated quadrivalent influenza vaccine.
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Table 5 Descriptive immunogenicity based on HI antibody titers in the per-protocol cohort for immunogenicity










QIV Day 0 1801 14.7 34.0 73.8 101.4
(13.8, 15.6) (31.8, 36.3) (69.1, 78.8) (94.5, 108.8)
Day 21 1809 201.1 314.7 404.6 601.8
(188.1, 215.1) 296.8, 333.6) (386.6, 423.4) (573.3, 631.6)
TIV-Vic Day 0 605 15.6 38.1 73.6 100.9
(14.1, 17.3) (34.1, 42.7) (65.5, 82.8) (89.3, 113.9)
Day 21 608 218.4 298.2 393.8 386.6
(194.2, 245.6) (268.4, 331.3) (362.7, 427.6) (351.5, 425.3)
TIV-Yam Day 0 530 14.4 35.7 71.7 99.8
(12.9, 16.0) (31.6, 40.3) (63.4, 81.0) (87.7, 113.5)
Day 21 534 213.0 340.4 258.5 582.5
(187.6, 241.9) (304.3, 380.9) (234.6, 284.8) (534.6, 634.7)
SPR, %
(95% CI)
QIV Day 0 1801 28.5% 53.6% 79.0% 83.0%
(26.5, 30.7) (51.2, 55.9) (77.1, 80.9) (81.1, 84.7)
Day 21 1809 91.3% 96.8% 98.8% 99.1%
(89.9, 92.5) (95.9, 97.6) (98.2, 99.3) (98.5, 99.5)
TIV-Vic Day 0 605 27.6% 58.3% 78.8% 82.1%
(24.1, 31.4) (54.3, 62.3) (75.4, 82.0) (78.9, 85.1)
Day 21 608 91.8% 95.9% 98.5% 97.9%
(89.3, 93.8) (94.0, 97.3) (97.2, 99.3) (96.4, 98.9)
TIV-Yam Day 0 530 26.2% 53.8% 77.7% 83.2%
(22.5, 30.2) (49.4, 58.1) (74.0, 81.2) (79.7, 86.3)
Day 21 534 92.7% 96.8% 96.1% 99.6%
(90.2, 94.8) (95.0, 98.1) (94.1, 97.5) (98.7, 100)
SCR, %
(95%)
QIV Day 21 1801 77.5% 71.5% 58.1% 61.7%
(75.5, 79.4) (69.3, 73.5) (55.8, 60.4) (59.5, 64.0)
TIV-Vic Day 21 605 77.2% 65.8% 55.4% 45.6%
(73.6, 80.5) (61.9, 69.6) (51.3, 59.4) (41.6, 49.7)
TIV-Yam Day 21 530 80.2% 70.0% 47.5% 59.1%
(76.5, 83.5) (65.9, 73.9) (43.2, 51.9) (54.7, 63.3)
SCF, value
(95%)
QIV Day 21 1801 13.69 9.28 5.48 5.93
(12.70, 14.76) (8.64, 9.96) (5.12, 5.85) (5.53, 6.36)
TIV-Vic Day 21 605 13.92 7.84 5.37 3.84
(12.23, 15.84) (6.93, 8.88) (4.75, 6.06) (3.42, 4.30)
TIV-Yam Day 21 530 14.88 9.52 3.60 5.84
(12.91, 17.16) (8.33, 10.89) (3.25, 3.98) (5.13, 6.65)
CI confidence interval, HI hemagglutination-inhibition, GMT geometric mean titer, SPR seroprotection rate, SCR seroconversion rate, SCF seroconversion factor,
QIV inactivated quadrivalent influenza vaccine, TIV-Vic inactivated trivalent influenza vaccine Victoria lineage B strain, TIV-Yam inactivated trivalent vaccine
Yamagata lineage B strain.
SPR defined as proportion of subjects with HI antibody titers ≥ 1:40; SCR defined as proportion of subjects with a pre-vaccination HI antibody titer < 1:10 and
post-vaccination HI antibody titer ≥ 1:40, or subjects with at least a 4-fold increase in the post-vaccination HI antibody titer; SCF defined as the geometric mean of
the within subject ratios of reciprocal HI antibody titers for post-vaccination versus pre-vaccination.
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diseases (excluding hypertension), diabetes and chronic
respiratory diseases (reported by 17%, 14% and 10% of the
subjects respectively) were the most frequently reported
risk factors for influenza disease complications. In each
group, about 80% of subjects had received at least one sea-
sonal influenza vaccine during the previous three seasons.
Immunogenicity
Confirmatory analyses
The limits of the two-sided 95% CI for the largest adjusted
GMT ratios at Day 21 among the three lots of QIV were
between 0.67 and 1.5 for each of the four strains, and
therefore the criteria for lot-to-lot consistency were met
(Table 2).
Non-inferior immunogenicity at Day 21 based on ad-
justed GMT ratio and SCR difference was shown for the
QIV candidate versus the TIV pooled for influenza A
strains, and versus TIV-Vic for B/Victoria, and TIV-Yam
for B/Yamagata (shared strains) (Table 3). Superior im-
munogenicity at Day 21 based on adjusted GMT ratio
and SCR difference was shown for the QIV candidate
versus TIV-Vic for B/Yamagata and versus TIV-Yam for
B/Victoria (alternate-lineage B strains) (Table 4).
Descriptive immunogenicity
The QIV candidate was highly immunogenic overall with
HI antibody-based SCRs of 77.5% and 71.5% against
A/H1N1 and A/H3N2, respectively, and 58.1% and
61.7% against B/Victoria and B/Yamagata, respectively
(Table 5). In the TIV groups overall, SCRs against influ-
enza A strains were 65.8–80.2%, and against B/Victoria
and B/Yamagata were 55.4% and 45.6%, respectively
for TIV-Vic, and 47.5% and 59.1% respectively for
TIV-Yam (Table 5). QIV elicited more than a 1.5-fold
higher mean HI antibody responses over each TIV
control for the influenza B strain from the alternate
lineage, which translated into an absolute SCR differ-
ence of at least 10.0%.
Age-stratified GMTs are shown in Figure 2, and age-
stratified SCRs and SPRs are shown in Figure 3. Age
stratified data showed that the HI antibody response
appeared to decrease with advancing age. The post-
vaccination HI antibody GMTs across all groups for all
vaccine strains were higher in subjects aged 18–64 years
(ranged between 294.3 and 749.1) compared with sub-
jects aged ≥ 65 years (ranged between 133.5 and 513.2).
The post-vaccination HI antibody GMT for the alternate-
lineage B strain was 436.4 for TIV-Vic and 259.9 for
TIV-Yam in subjects 18–64 years, and 339.5 and 257.0, re-
spectively, in subjects aged ≥ 65 years. The SCRs for all
vaccine strains across all study groups were 60.5 –82.7%
in subjects aged 18–64 years, and 45.4%–78.8% in subjects
aged ≥ 65 years. The SCRs for the alternate-lineage B
strain was 48.7% for TIV-Vic and 51.3% for TIV-Yam in
subjects 18–64 years, and 42.3% and 43.6%, respectively in
subjects aged ≥ 65 years. In the QIV group, the SCRs for
all vaccine strains were 66.9–82.7% in subjects aged 18–
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Figure 2 HI antibody GMTs stratified by age (per-protocol immunogenicity sub-cohort). Footnote: CI, confidence interval; GMT, geometric
mean titer; QIV, inactivated quadrivalent influenza vaccine; TIV-Vic, inactivated trivalent influenza vaccine Victoria lineage B strain; TIV-Yam,
inactivated trivalent influenza vaccine Yamagata lineage B strain.
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Reactogenicity and safety
Reactogenicity during the 7-day post-vaccination period is
shown in Figure 4. Injection site pain was the most fre-
quent local symptom, and was reported by 36.4%, 36.8%
and 31.3% of the QIV, TIV-Vic, and TIV-Yam groups re-
spectively. Grade 3 solicited injection site symptoms were
reported for ≤ 1.2% of subjects in any group. In the QIV,
TIV-Vic and TIV-Yam groups, the most frequent general
symptoms were fatigue (15.8%, 18.4% and 14.8%, re-
spectively), headache (15.9%, 16.4% and 13.2%, re-
spectively) and muscle ache (16.4%, 19.4% and 16.1%,
respectively). Grade 3 solicited general symptoms
were reported in < 1.0% of subjects in any group.
An overview of unsolicited AEs and MAEs is shown in
Table 6. Overall during the 21-day post-vaccination
follow-up period (Day 0 to Day 20) in the QIV, TIV-Vic,
and TIV-Yam groups, respectively, 379 (12.5%), 138
(13.7%) and 92 (15.1%), subjects reported at least 1 un-
solicited AE. Grade 3 AEs were reported by ≤ 1.3% of
subjects. Nasopharyngitis and cough were the most fre-
quently reported unsolicited AEs in each group (1.4%–
1.7%). Overall, ≤ 2.6% of subjects reported AEs that were
considered by the investigator to be related to vaccin-
ation. During the 21-day post-vaccination period, in the
QIV, TIV-Vic, and TIV-Yam groups, respectively, 193
(6.4%), 60 (5.9%) and 47 (7.7%), subjects reported at
least 1 MAE. In the QIV group, the most frequent
MAEs during the 21 day post-vaccination period were
nasopharyngitis (0.8%) and cough (0.5%), in the TIV-Vic
group were nasopharyngitis (0.8%) and sinusitis (0.4%),
and in the TIV-Yam group were nasopharyngitis (0.8%)
and urinary tract infection (0.7%). During the 6 month
follow-up, MAEs were reported by 688 (22.7%) and 216
(21.4%) subjects in the QIV group and in the TIV-Vic
group, respectively.
During the 21-day post-vaccination period in the QIV,
TIV-Vic, and TIV-Yam groups, respectively, 16 (0.5%), 6
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(B strain Yamagata lineage)
B/Brisbane/3/2007 
(B strain Yamagata lineage)
Figure 3 HI antibody stratified by age (per-protocol immunogenicity sub-cohort). Footnote: (A). seroconversion rate, (B). seroprotection
rate. CI, confidence interval; QIV, Inactivated quadrivalent influenza vaccine; TIV-Vic, inactivated trivalent influenza vaccine Victoria lineage B strain;
TIV-Yam, inactivated trivalent influenza vaccine Yamagata lineage B strain. Seroconversion rate defined as the proportion with antibody titer
< 1:10 at baseline and with post-vaccination titer of ≥ 1:40, or pre-vaccination titer of ≥ 1:10 and a ≥ 4-fold post-vaccination increase in titer;
Seroprotection rate defined as defined as proportion with post-vaccination titer ≥ 1:40.
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During the 6 month follow-up, 98 SAEs were reported
by 70 subjects (2.3%) in the QIV group and 27 SAEs
were reported by 26 subjects (2.6%) in the TIV-Vic
group. The most frequent SAE(s) in the QIV group were
myocardial infarction and cerebrovascular accident (5 re-
ports each; 0.2%), in the TIV-Vic group was pneumonia,
cerebrovacular accident and nephrolithiasis (2 reports
each; 0.2%), and in the TIV-Yam group the only SAE was
arteriosclerosis. Twelve subjects, all aged ≥ 65 years, died
during the study (Table 7). There were 9 deaths in the QIV
group (2 cardiac disorders, 1 neoplasm, 1 intestinal infarc-
tion, 2 sudden deaths, 1 hepatic coma, 1 cerebrovascular
accident and 1 pulmonary hypertension). There were 3
deaths in the TIV-Vic group, all due to cardiac disorders.
None of the deaths were considered by the investigator to
be related to vaccination.
Discussion
This Phase III, randomized study showed that HI anti-
body responses of a candidate QIV were non-inferior for
shared influenza A and B vaccine strains, and superior
for alternate-lineage influenza B strains compared with
TIV in adults aged ≥ 18 years in stable health. Manufac-
turing consistency of HI antibody responses was also
demonstrated for three QIV vaccine lots. The candidate
QIV had an acceptable reactogenicity and safety profile
which was consistent with that of TIV. These results
show that the candidate QIV provided superior im-
munogenicity for the additional B strain compared with
TIV, without interfering with antibody responses to the
three TIV antigens. This suggests that the candidate

















































Hatched boxes: Grade 3
Figure 4 Solicited adverse events (total vaccinated cohort).
Footnote: (A). local adverse events, (B). general adverse events. CI,
confidence interval; GI, gastrointestinal; QIV, Inactivated quadrivalent
influenza vaccine; TIV-Vic, inactivated trivalent influenza vaccine
Victoria lineage B strain; TIV-Yam, inactivated trivalent influenza
vaccine Yamagata lineage B strain.
Table 6 Overview of unsolicited AEs and MAEs in the total vaccinated cohort
QIV TIV-Vic TIV-Yam
N = 3036 N = 1010 N = 610
Adverse events Day 0–20, n (%)
Subjects with ≥ 1 event 379 (12.5) 138 (13.7) 92 (15.1)
Subjects with ≥ 1 Grade 3 event 39 (1.3) 7 (0.7) 2 (0.3)
Subjects with ≥ 1 event related to vaccination† 64 (2.1) 26 (2.6) 14 (2.3)
No. of events by MedDRA preferred term 558 195 125
No. of Grade 3 events by MedDRA preferred term 52 8 2
No. of events by MedDRA preferred term related to vaccination† 89 38 16
Medically-attended adverse events Day 0–20, n (%)
Subjects with ≥ 1 event 193 (6.4) 60 (5.9) 47 (7.7)
No. of events by MedDRA preferred term 250 75 63
Medically-attended adverse events Day 0–180, n (%)
Subjects with ≥ 1 event 688 (22.7) 216 (21.4) NA*
No. of events by MedDRA preferred term 1151 379 NA*
AE adverse event, MAE medically-attended adverse event, QIV inactivated quadrivalent influenza vaccine, TIV-Vic inactivated trivalent influenza vaccine Victoria
lineage B strain, TIV-Yam inactivated trivalent influenza vaccine Yamagata lineage B strain, MedDRA Medical Dictionary for Regulatory Activities, NA not applicable,
†Based on investigator’s assessment of causality; *TIV-YAM group was followed up until Day 21.
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aged ≥ 18 years, and could potentially improve protec-
tion against influenza B.
Influenza vaccines offer the greatest protection against
influenza strains matched to the vaccine strains, and
when there is a B-lineage mismatch, vaccine protection
is reduced [8,9,16]. Indeed, the control TIV used in our
study has been previously shown to be associated with
vaccine efficacy of 67% (95% CI: 52, 77) in adults aged
18–64 years against vaccine-matching, culture-confirmed
influenza, whereas in another study conducted during a
season when viral circulation of influenza A was low, and
the vaccine was mismatched to the prevalent influenza B
virus, vaccine efficacy was not significant versus placebo
[17,18]. A QIV containing strains from both B lineages
could eliminate the risk of B lineage mismatch and
be expected to provide improved protection against
influenza B [11].
The candidate QIV in our study had superior antibody
responses for the additional B strain compared with each
TIV in which the strain was absent. However, whenever
additional antigens are added to a vaccine, it is necessary
to ensure that new antigens do not interfere with the
immunogenicity of the existing vaccine antigens. For
the candidate QIV in our study, the absence of im-
munologic interference was established by demonstrating
non-inferiority between HI antibody responses elicited by
the candidate QIV and TIV-Vic and TIV-Yam for the
shared TIV strains. We showed that QIV elicited strong
HI antibody responses, with SCRs of 77.5% and 71.5%
against A/H1N1 and A/H3N2, respectively, 58.1% against
B/Victoria, and 61.7% against B/Yamagata.
Influenza B is thought to disproportionately affect chil-
dren and young people, and in adults, particularly eld-
erly adults, influenza A (notably H3N2) is reported to be
associated with higher rates of influenza-related compli-
cations and deaths than influenza B [19]. Nonetheless,
influenza B epidemics in adults about every 2–4 years,
and infection with influenza B virus confers an import-
ant risk of severe illness and hospitalization [19-22].
Moreover, in a modeling study of viral respiratory dis-
ease among hospitalized patients based on data from the
UK, whereas influenza A was found to represent the
highest ranking burden based on disability-adjusted-life-
years among patients aged 16–64 and > 65 years, influ-
enza B ranked fourth and second in the younger and
older age groups, respectively [23]. A major finding of
the modeling study was that the burden of influenza B
disease was 100-fold higher in the > 65 years group
than the 18–64 years group, whereas the corresponding
increase between young and old for influenza A was
about 50-fold [23].
In our sub-group analysis by age, although immune re-
sponses were generally lower for subjects aged ≥ 65 years
than those aged 18–65 years, the QIV candidate was im-
munogenic for all four vaccine strains, and HI antibody
responses against all strains fulfilled CBER immunogen-
icity acceptance criteria in both age strata [24]. TIV also
elicited robust antibody responses against the three vac-
cine strains. The responses against alternate-lineage B
strains were lower than the response observed for the B
strain contained in the vaccine. The proportion of sub-
jects overall with pre-vaccination antibody titers of ≥1:40
Table 7 Description of fatal SAEs in the total vaccinated cohort
Vaccine group Subject code Country Age at onset,
years
Gender MedDRA Preferred term Day of onset
post-vaccination
QIV N = 3036 461 Taiwan 85 M Sudden death 86
2140 Republic of Korea 85 F Cardiac failure congestive Myocardial infarction 131
3023 Germany 84 F Death 62
4373 Romania 81 F Cardiopulmonary failure 87
Intestinal infarction 86
6609 US 71 M Pulmonary hypertension 162
7347 US 72 F Myocardial infarction 35
987 Republic of Korea 68 F Coma hepatic 95
5468 Spain 73 M Cerebrovascular accident 191
6594 US 71 F Small cell lung cancer stage unspecified 51
TIV-Vic N = 1010 3735 Romania 86 M Cardiac arrest 75
Myocardial infarction
4362 Romania 69 M Cardio-respiratory arrest 97
5518 Spain 69 M Cardiac disorder 15
SAE serious adverse event, QIV inactivated quadrivalent influenza vaccine, TIV-Vic inactivated trivalent influenza vaccine Victoria lineage B strain, MedDRA Medical
Dictionary for Regulatory Activities, F female, M male.
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against B/Yamagata in the TIV-Vic group was 82.1% and
against B/Victoria in the TIV-Yam group was 77.7%.
High baseline antibody levels to influenza B strains from
both lineages are likely to have facilitated booster re-
sponses to the B lineage absent from each TIV control
group. Nevertheless, cross reactive HI antibody may not
correlate with protection, as very high rates of break-
through infections have been observed in elderly popula-
tions exposed to vaccine-lineage mismatched influenza B
viruses even when vaccination elicited good cross-reactive
HI booster responses [25].
We previously evaluated the immunogenicity of the
QIV candidate in adults aged 18–60 years in a Phase II
trial conducted in the Czech Republic between July and
August 2008, and the GMT ratios confirming superior
immunogenicity for the B strain unique to the QIV can-
didate were notably higher than in the current Phase III
study [Phase II study under review for publication]. In
the Phase II study, the GMT ratio for QIV/TIV-Vic
against B/Yamagata was 4.08 (95% CI: 3.26, 5.11) com-
pared with 1.55 (95% CI: 1.41, 1.70) in the Phase III
study; however, in the Phase II study, the pre- and post-
vaccination GMTs against B/Yamagata were 19.2 and
43.4 (TIV-Vic) and 19.6 and 179.1 (QIV), compared with
100.9 and 386.6 (TIV-Vic) and 101.4 and 601.8 (QIV) in
the Phase III study. The difference in GMT ratio ob-
served in the Phase II and Phase III studies likely reflects
differences between the study populations regarding
their recent prior exposure to influenza B viruses. For
example, in the Phase III study, about 60% and 70% of
participants respectively received TIV in 2008–2009
and 2009–2010, which sequentially contained the same
B/Yamagata and B/Victoria strain contained in the present
QIV candidate. Indeed, the superior immunogenicity of
the QIV candidate versus TIV for the additional B strain
would likely vary year to year, and as such, potentially
improved protection may also vary. Nevertheless, this
Phase III study provides a conservative estimate of super-
ior immunogenicity, given the relatively high baseline anti-
body levels against each B lineage.
Because the QIV contains 60 μg of influenza antigen,
it was possible that reactogenicity could be higher than
with the TIV, which contains 45 μg of antigen. In this
study, however, the reactogenicity and safety profile of
the QIV candidate was consistent with the TIVs. None
of the SAEs observed during the six month follow-up
were considered by the investigators to be related to the
study vaccines. The results suggest that the inclusion of
an additional 15 μg of antigen in the QIV candidate did
not compromise safety compared with TIV.
A limitation of the study was a concern regarding the
compliance with Good Clinical Practice at a single study
site in Romania which enrolled 45 subjects in the trial.
A sensitivity analysis excluding data from this site was
performed which did not impact study conclusions;
therefore, data from this site were not excluded from the
final analyses.
Conclusions
In conclusion, because TIVs contain only one influenza
B strain, vaccine mismatch for the alternate-lineage B
strain is frequent, resulting in reduced vaccine protec-
tion. In this study of adults and elderly adults, we
showed that a QIV candidate versus TIV provided non-
inferior immunogenicity for shared influenza A and B
strains, while also providing superior immunogenicity
for the additional B strain. The reactogenicity and safety
profile of the QIV candidate was consistent with TIV.
These results suggest that a switch from TIV to QIV is a
viable approach to influenza vaccination with the aim of
eliminating influenza B lineage mismatch to potentially
improve protection against influenza B.
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